|By PR Newswire||
|February 25, 2014 06:01 AM EST||
SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS™). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.
The Imprimis Pharmaceuticals proprietary ophthalmic therapies that Dr. Lewis will showcase during his presentation were prescribed by Dr. Lewis for more than 400 cataract surgery patients, and include a formulation combining triamcinolone acetonide, moxifloxacin hydrochloride and the antibiotic vancomycin. A second formulation is available with triamcinolone acetonide and moxifloxacin hydrochloride. Both of these proprietary formulations have been used by select physicians during thousands of cataract surgeries and many other eye surgeries where, as a result of the surgery, there is inflammation and a chance for post-operative infection. Dr. Lewis's presentation will include video in which he demonstrates a transzonular approach for the injection of the drugs intraoperatively. He will also examine the benefits of dropless cataract surgery for both doctors and patients. Dr. Lewis is not an employee or consultant of Imprimis.
This presentation by Dr. Lewis builds on Imprimis' strong momentum from participation at previous meetings, including the American Academy of Ophthalmology in New Orleans, La., the "Cataract Surgery: Telling It Like It is" meeting in Sarasota, Fla., and the Caribbean Eye Meeting in Cancun, Mexico. In addition to its presence at these meetings, the company has held several Ophthalmic Advisory Board meetings with national thought leaders. Each of these events provides the opportunity to build relationships and gain valuable insight on the company's innovations and business model from the perspective of the ophthalmic surgeons who participate.
Imprimis previously announced plans to make available its proprietary ophthalmic compounded therapies during the first half of 2014, and is continuing its Go Dropless™ campaign (http://GoDropless.com/). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS
Imprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.
Imprimis believes that its proprietary formulations may have a broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market where the company believes there is an opportunity for technological advancement to meet patient interest to reduce or eliminate the need for post-surgery eye drops. The cataract surgery market continues exponential growth. Nearly 22 million cataract surgeries were performed globally in 2013, according to Market Scope.1 This growth is not only due to the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic2, portending the ophthalmology drug market to reach an estimated $21.6 billion by 20183.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending drug formulations are available today and are being prescribed by physicians. For more information, please visit www.imprimispharma.com or www.GoDropless.com.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make available its formulations during the expected timeframe or at all; physician interest in prescribing its formulations, Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction and enter , into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to commercialize its formulations and technologies, obtain intellectual property protection for its assets, its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary, risks related to research and development activities;, the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
MEDIA CONTACT: Jen Carroll
SOURCE Imprimis Pharmaceuticals, Inc.
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Oct. 23, 2016 09:45 PM EDT Reads: 1,855
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Oct. 23, 2016 09:30 PM EDT Reads: 2,440
November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Penta Security is a leading vendor for data security solutions, including its encryption solution, D’Amo. By using FPE technology, D’Amo allows for the implementation of encryption technology to sensitive data fields without modification to schema in the database environment. With businesses having their data become increasingly more complicated in their mission-critical applications (such as ERP, CRM, HRM), continued ...
Oct. 23, 2016 09:15 PM EDT Reads: 967
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
Oct. 23, 2016 09:00 PM EDT Reads: 732
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Oct. 23, 2016 09:00 PM EDT Reads: 5,989
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captu...
Oct. 23, 2016 09:00 PM EDT Reads: 1,511
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, will draw together recent research and lessons learned from emerging and established ...
Oct. 23, 2016 09:00 PM EDT Reads: 1,246
SYS-CON Events announced today that Enzu will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their online busine...
Oct. 23, 2016 08:45 PM EDT Reads: 1,285
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Oct. 23, 2016 08:30 PM EDT Reads: 1,706
SYS-CON Events announced today that Cloudbric, a leading website security provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Cloudbric is an elite full service website protection solution specifically designed for IT novices, entrepreneurs, and small and medium businesses. First launched in 2015, Cloudbric is based on the enterprise level Web Application Firewall by Penta Security Sys...
Oct. 23, 2016 08:30 PM EDT Reads: 1,102
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Oct. 23, 2016 08:00 PM EDT Reads: 3,965
SYS-CON Events announced today that Roundee / LinearHub will exhibit at the WebRTC Summit at @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LinearHub provides Roundee Service, a smart platform for enterprise video conferencing with enhanced features such as automatic recording and transcription service. Slack users can integrate Roundee to their team via Slack’s App Directory, and '/roundee' command lets your video conference ...
Oct. 23, 2016 07:30 PM EDT Reads: 2,067
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Oct. 23, 2016 07:00 PM EDT Reads: 4,557
Established in 1998, Calsoft is a leading software product engineering Services Company specializing in Storage, Networking, Virtualization and Cloud business verticals. Calsoft provides End-to-End Product Development, Quality Assurance Sustenance, Solution Engineering and Professional Services expertise to assist customers in achieving their product development and business goals. The company's deep domain knowledge of Storage, Virtualization, Networking and Cloud verticals helps in delivering ...
Oct. 23, 2016 06:45 PM EDT Reads: 1,009
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Oct. 23, 2016 05:30 PM EDT Reads: 843